Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPS002
MIFTS: 65

Liposarcoma

Categories: Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liposarcoma

About this section

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 12 74 52 54 43 15 17 71

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Liposarcoma

About this section
NIH Rare Diseases : 52 Liposarcoma is a tumor that arises from fat tissue . This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen , but it can be found in other parts of the body, in the retroperitoneum ; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs , it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell ; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation . Most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. In the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. In general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. The patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. Patients may report the following: Associated episode of trauma to the region containing the mass Painful swelling (occurs in one third of cases for as long as 6 mo) Decreased function (ie, range of motion) Numbness Enlargement of varicose veins Fatigue Abdominal pain Weight loss Nausea Vomiting

MalaCards based summary : Liposarcoma is related to mediastinum liposarcoma and myxoid liposarcoma. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Endometrial cancer. The drugs Lenograstim and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and adipocyte, and related phenotypes are subcutaneous nodule and sarcoma

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.

Wikipedia : 74 Liposarcoma is a cancer that arises in fat cells in soft tissue, such as that inside the thigh or in the... more...

Sources

Related Diseases for Liposarcoma

About this section

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 656)
# Related Disease Score Top Affiliating Genes
1 mediastinum liposarcoma 34.8 MDM2 CDKN2A CDK4
2 myxoid liposarcoma 34.5 YBX1 TSN TP53 MDM2 HMGA2 FUS
3 cellular myxoid liposarcoma 34.4 MDM2 FUS EWSR1 DDIT3 CDK4
4 adult liposarcoma 34.4 MDM2 CDK4
5 gastric liposarcoma 34.4 MDM2 CDK4 CD34
6 sclerosing liposarcoma 34.4 MDM2 FUS CD34
7 inflammatory liposarcoma 34.3 MDM2 CDKN2A CD34
8 mixed liposarcoma 34.3 MDM2 FUS DDIT3 CDK4 CD34
9 spindle cell liposarcoma 34.3 MDM2 DDIT3 CDK4 CD34
10 liposarcoma of bone 34.2 MYOG MDM2 CDK4 CD34
11 pleomorphic liposarcoma 34.0 VIM MDM2 FUS EWSR1 DES DDIT3
12 well-differentiated liposarcoma 34.0 TP53 MYOG MDM2 HMGA2 FUS EWSR1
13 pediatric liposarcoma 33.8 VIM MDM2 HMGA2 FUS DDIT3 CDK4
14 dedifferentiated liposarcoma 33.3 TP53 RB1 PPARG MYOG MDM2 MB
15 soft tissue sarcoma 32.3 TP53 MDM2 EWSR1
16 pleomorphic lipoma 32.2 MDM2 HMGA2 CDK4 CD34
17 lipomatosis, multiple 31.7 MDM2 HMGA2 FUS EWSR1 DES DDIT3
18 rare tumor 31.6 EWSR1 DES
19 fibrosarcoma 31.5 VIM TP53 EWSR1 DES
20 lipoblastoma 31.4 MDM2 CDK4
21 osteogenic sarcoma 31.4 TP53 RB1 MDM2 CDKN2A CDK4
22 mesenchymal cell neoplasm 31.3 TP53 MYOG HMGA2 EWSR1 CD34
23 fibrous histiocytoma 31.3 VIM TP53 MYOG FUS EWSR1 DES
24 retroperitoneal sarcoma 31.2 MYOG MDM2 EWSR1 CDK4 CD34
25 chondrosarcoma 31.2 VIM MDM2 EWSR1 CDK4
26 spindle cell sarcoma 31.2 VIM MYOG MDM2 GPS2 DES CD34
27 familial retinoblastoma 31.1 TP53 RB1 MDM2 CDKN2A CDK4
28 malignant mesenchymoma 31.1 MYOG MDM2 MB DES CD34
29 malignant fibrous histiocytoma 31.1 VIM TP53 MYOG MDM2 MB FUS
30 infiltrating lipoma 31.1 MDM2 HMGA2 CDK4 CD34
31 li-fraumeni syndrome 31.0 TP53 RB1 MDM2 CDKN2A CDK4
32 leiomyoma 31.0 VIM HMGA2 DES CD34
33 spindle cell lipoma 31.0 VIM RB1 MDM2 DES CDK4 CD34
34 embryonal sarcoma 31.0 VIM TP53 MYOG MDM2 DES CDK4
35 retinoblastoma 31.0 TP53 RB1 PPARG MDM2 CDKN2A CDK4
36 angiolipoma 30.9 VIM MDM2 DES CD34
37 myxofibrosarcoma 30.9 TP53 MYOG MDM2 FUS EWSR1 DES
38 pleomorphic rhabdomyosarcoma 30.9 TP53 MYOG MB
39 leiomyosarcoma 30.9 VIM TP53 RB1 MYOG MDM2 MB
40 gastrointestinal stromal tumor 30.9 VIM TP53 DES CDKN2A CD34
41 thymus lipoma 30.8 MB FUS
42 sarcoma 30.8 VIM TP53 RB1 MYOG MDM2 FUS
43 juxtacortical osteosarcoma 30.8 MDM2 EWSR1 CDK4
44 neurofibroma 30.8 VIM TP53 CDKN2A CD34
45 retroperitoneal fibrosis 30.8 VIM MDM2
46 teratoma 30.8 VIM TP53 CDKN2A CALB2
47 adrenal cortical carcinoma 30.7 VIM TP53 CALB2
48 benign mesothelioma 30.7 CD34 CALB2
49 breast fibroadenoma 30.7 TP53 HMGA2 CD34
50 chondroid lipoma 30.7 HMGA2 CD34

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma
Sources

Symptoms & Phenotypes for Liposarcoma

About this section

Human phenotypes related to Liposarcoma:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 subcutaneous nodule 31 hallmark (90%) HP:0001482
2 sarcoma 31 hallmark (90%) HP:0100242
3 fatigue 31 occasional (7.5%) HP:0012378
4 weight loss 31 occasional (7.5%) HP:0001824
5 nausea and vomiting 31 occasional (7.5%) HP:0002017
6 abdominal pain 31 occasional (7.5%) HP:0002027
7 paresthesia 31 occasional (7.5%) HP:0003401
8 varicose veins 31 occasional (7.5%) HP:0002619
9 abnormality of the kidney 31 occasional (7.5%) HP:0000077

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD34 CDK4 DDIT3 DES MDM2 PPARG

MGI Mouse Phenotypes related to Liposarcoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 CD34 CDK4 CDKN2A DDIT3 DES MB
2 behavior/neurological MP:0005386 10.3 CALB2 CDK4 CDKN2A DDIT3 DES MDM2
3 cardiovascular system MP:0005385 10.29 CDK4 CDKN2A DDIT3 DES MB MDM2
4 homeostasis/metabolism MP:0005376 10.28 CD34 CDK4 CDKN2A DDIT3 DES MB
5 growth/size/body region MP:0005378 10.23 CDK4 CDKN2A DDIT3 MB MDM2 MYOG
6 hematopoietic system MP:0005397 10.21 CD34 CDK4 CDKN2A DDIT3 MB MDM2
7 embryo MP:0005380 10.18 CDK4 CDKN2A MB MDM2 MYOG PPARG
8 immune system MP:0005387 10.11 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARA
9 adipose tissue MP:0005375 10.08 DDIT3 MYOG PPARA PPARG RB1 TP53
10 integument MP:0010771 10.02 CD34 CDK4 CDKN2A MDM2 MYOG PPARA
11 mortality/aging MP:0010768 9.97 CDK4 CDKN2A DES GPS2 MB MDM2
12 liver/biliary system MP:0005370 9.91 CDK4 CDKN2A DDIT3 MDM2 PPARA PPARG
13 muscle MP:0005369 9.7 CDK4 CDKN2A DES MB MDM2 MYOG
14 neoplasm MP:0002006 9.23 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARG
Sources

Drugs & Therapeutics for Liposarcoma

About this section

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
11
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
12 Olaratumab Approved, Investigational Phase 3 1024603-93-7
13
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
14
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
15
Histamine Approved, Investigational Phase 3 51-45-6 774
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17 Pharmaceutical Solutions Phase 3
18 Tubulin Modulators Phase 3
19 Antimitotic Agents Phase 3
20 Etoposide phosphate Phase 3
21 Anti-Bacterial Agents Phase 3
22 Antibiotics, Antitubercular Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24
Isophosphamide mustard Phase 2, Phase 3 0
25 Gastrointestinal Agents Phase 3
26 Neurotransmitter Agents Phase 3
27 Histamine Antagonists Phase 3
28 Anti-Allergic Agents Phase 3
29
Histamine Phosphate Phase 3 51-74-1 65513
30 Histamine H1 Antagonists Phase 3
31 Dermatologic Agents Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
35
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
36
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
40
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
43
nivolumab Approved Phase 1, Phase 2 946414-94-4
44
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
45
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
46
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
47
Lenvatinib Approved, Investigational Phase 1, Phase 2 417716-92-8
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
50
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
2 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
3 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
6 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
7 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
8 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
9 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
10 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
12 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
13 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
14 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
15 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
17 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
18 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
19 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
20 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
21 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
22 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
23 A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation Unknown status NCT00633165 Phase 2 Brostallicin
24 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
25 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
26 Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma Unknown status NCT01841047 Phase 2
27 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
28 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
29 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
30 Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial Unknown status NCT01900743 Phase 2 Regorafenib;Placebo
31 A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
32 Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma Completed NCT00003058 Phase 2 troglitazone
33 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
34 Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
35 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
36 A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
37 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
38 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
39 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
40 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Completed NCT02609984 Phase 2
41 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
42 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
43 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
44 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
45 Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
46 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
47 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
48 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
49 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
50 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Sources

Genetic Tests for Liposarcoma

About this section
Sources

Anatomical Context for Liposarcoma

About this section

MalaCards organs/tissues related to Liposarcoma:

40
Bone, Breast, Adipocyte, Kidney, Lung, T Cells, Skin
Sources

Publications for Liposarcoma

About this section

Articles related to Liposarcoma:

(show top 50) (show all 5679)
# Title Authors PMID Year
1
Neuronal death in amyotrophic lateral sclerosis (ALS): what can we learn from genetics? 61 54
20406185 2010
2
The role of autophagy: what can be learned from the genetic forms of amyotrophic lateral sclerosis. 54 61
20406184 2010
3
Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. 54 61
20406182 2010
4
Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. 54 61
20228779 2010
5
Specificity of fusion genes in adipocytic tumors. 61 54
20332486 2010
6
Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. 54 61
20224740 2010
7
[Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. 61 54
19823827 2010
8
Well-differentiated and dedifferentiated liposarcomas. 54 61
19688222 2010
9
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. 54 61
19820690 2009
10
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 54 61
19946100 2009
11
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. 54 61
19626636 2009
12
Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. 54 61
19734852 2009
13
Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma. 61 54
19525929 2009
14
Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus. 54 61
19608085 2009
15
Structural basis and specificity of human otubain 1-mediated deubiquitination. 61 54
18954305 2009
16
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 54 61
18820664 2009
17
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 61 54
18836421 2009
18
Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity. 54 61
18551309 2008
19
SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. 54 61
18580682 2008
20
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 61 54
18500263 2008
21
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. 61 54
18596980 2008
22
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. 54 61
18509338 2008
23
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 54 61
18204431 2008
24
[Retroperitoneal giant mixed sarcoma. Case report]. 54 61
18507961 2008
25
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. 61 54
18414473 2008
26
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma. 54 61
18438568 2008
27
Clinical Use of PPARgamma Ligands in Cancer. 61 54
19125177 2008
28
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 61 54
17638873 2007
29
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. 54 61
17359542 2007
30
Pathology and genetics of adipocytic tumors. 54 61
18000364 2007
31
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. 61 54
17214366 2006
32
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. 61 54
17018606 2006
33
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 61 54
16707369 2006
34
Calretinin expression in tumors of adipose tissue. 54 61
16613326 2006
35
A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. 54 61
16405554 2006
36
Round cell liposarcoma of scrotum with indolent course in young adult. 61 54
16536120 2005
37
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. 54 61
15688424 2005
38
Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. 61 54
15551306 2005
39
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. 54 61
15064749 2004
40
[From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors]. 54 61
15242313 2004
41
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. 61 54
12551936 2003
42
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 61 54
12640106 2003
43
Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma--A microdissection approach. 54 61
12924448 2003
44
Current strategies for anticancer chemoprevention and chemoprotection. 54 61
12669776 2002
45
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. 61 54
12353276 2002
46
A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. 61 54
12169678 2002
47
RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. 54 61
12168660 2002
48
The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. 54 61
11604390 2001
49
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. 61 54
11494023 2001
50
Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). 54 61
11530334 2001
Sources

Variations for Liposarcoma

About this section

Cosmic variations for Liposarcoma:

9 (show top 50) (show all 964)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149329806 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 12
2 COSM101976918 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 12
3 COSM91381057 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
4 COSM85719005 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
5 COSM87898709 TP53 soft tissue,fat,liposarcoma,pleomorphic c.742C>T p.R248W 17:7674221-7674221 12
6 COSM88042811 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 12
7 COSM87935416 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 12
8 COSM87967829 TP53 soft tissue,fat,liposarcoma,pleomorphic c.421T>G p.C141G 17:7675191-7675191 12
9 COSM87912393 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 12
10 COSM87908091 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 17:7675208-7675208 12
11 COSM87906877 TP53 soft tissue,fat,liposarcoma,pleomorphic c.493C>T p.Q165* 17:7675119-7675119 12
12 COSM87898758 TP53 soft tissue,fat,liposarcoma,pleomorphic c.707A>G p.Y236C 17:7674256-7674256 12
13 COSM87897745 TP53 soft tissue,fat,liposarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 12
14 COSM133378945 TET2 soft tissue,fat,liposarcoma,myxoid-round cell c.3809C>T p.T1270I 4:105259624-105259624 12
15 COSM84144724 SDHA soft tissue,fat,liposarcoma,myxoid-round cell c.664T>G p.L222V 5:228227-228227 12
16 COSM84143247 RICTOR soft tissue,fat,liposarcoma,pleomorphic c.3404C>T p.T1135M 5:38950444-38950444 12
17 COSM86627654 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 13:48456207-48456207 12
18 COSM86629113 RB1 soft tissue,fat,liposarcoma,pleomorphic c.2632G>A p.D878N 13:48476812-48476812 12
19 COSM85622159 RAF1 soft tissue,fat,liposarcoma,pleomorphic c.1141G>A p.D381N 3:12591760-12591760 12
20 COSM96852740 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.106G>A p.G36R 10:87894051-87894051 12
21 COSM96850334 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.335T>C p.L112P 10:87933094-87933094 12
22 COSM96844976 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.485A>T p.D162V 10:87933244-87933244 12
23 COSM96843637 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.518G>A p.R173H 10:87952143-87952143 12
24 COSM90596352 POLE soft tissue,fat,liposarcoma,myxoid-round cell c.2275C>T p.R759C 12:132667547-132667547 12
25 COSM86135850 PLK2 soft tissue,fat,liposarcoma,myxoid-round cell c.1337G>C p.R446P 5:58456073-58456073 12
26 COSM87132308 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 3:179218303-179218303 12
27 COSM87132301 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1624G>A p.E542K 3:179218294-179218294 12
28 COSM87132245 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3140A>G p.H1047R 3:179234297-179234297 12
29 COSM87133148 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3145G>C p.G1049R 3:179234302-179234302 12
30 COSM87132330 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1035T>A p.N345K 3:179203765-179203765 12
31 COSM88395167 NOTCH2 soft tissue,fat,liposarcoma,myxoid-round cell c.5857C>T p.R1953C 1:119918478-119918478 12
32 COSM93657303 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 17:31201079-31201079 12
33 COSM93651081 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 17:31249015-31249015 12
34 COSM87492291 NCOR1 soft tissue,fat,liposarcoma,myxoid-round cell c.4256C>T p.P1419L 17:16070422-16070422 12
35 COSM97248342 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.536G>A p.R179H 1:45332794-45332794 12
36 COSM97249804 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.1022C>T p.P341L 1:45331816-45331816 12
37 COSM85277257 MLH1 soft tissue,fat,liposarcoma,myxoid-round cell c.2146G>A p.V716M 3:37050528-37050528 12
38 COSM87804068 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 12:25245351-25245351 12
39 COSM88437574 KMT2C soft tissue,fat,liposarcoma,pleomorphic c.12200C>A p.P4067H 7:152154086-152154086 12
40 COSM129135588 KMT2A soft tissue,fat,liposarcoma,pleomorphic c.8095C>T p.R2699* 11:118503987-118503987 12
41 COSM129120591 KMT2A soft tissue,fat,liposarcoma,myxoid-round cell c.5792G>T p.G1931V 11:118498063-118498063 12
42 COSM88326583 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 4:54731971-54731971 12
43 COSM102161049 KDM6A soft tissue,fat,liposarcoma,pleomorphic c.3768C>G p.Y1256* 23:45090754-45090754 12
44 COSM90627870 JAK1 soft tissue,fat,liposarcoma,pleomorphic c.1595G>A p.R532H 1:64855562-64855562 12
45 COSM92324126 GATA2 soft tissue,fat,liposarcoma,myxoid-round cell c.436G>A p.G146S 3:128486162-128486162 12
46 COSM86840055 FLCN soft tissue,fat,liposarcoma,pleomorphic c.247G>A p.E83K 17:17227891-17227891 12
47 COSM110445901 FAT1 soft tissue,fat,liposarcoma,pleomorphic c.2806G>A p.V936I 4:186707022-186707022 12
48 COSM88598739 ERBB2 soft tissue,fat,liposarcoma,pleomorphic c.2441G>A p.R814H 17:39724859-39724859 12
49 COSM143832241 EPHA5 soft tissue,fat,liposarcoma,pleomorphic c.1705G>A p.D569N 4:65404462-65404462 12
50 COSM86767254 EPCAM soft tissue,fat,liposarcoma,myxoid-round cell c.457A>G p.R153G 2:47375265-47375265 12

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma
Sources

Expression for Liposarcoma

About this section
Search GEO for disease gene expression data for Liposarcoma.
Sources

Pathways for Liposarcoma

About this section

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 65
Show member pathways
 13.1 TP53 RB1 MDM2 HMGA2 CDKN2A CDK4
2
Endometrial cancer 36
Show member pathways
 12.81 TP53 RB1 PPARG MDM2 CDKN2A CDK4
3
Pathways in cancer 36
12.78 TP53 RB1 PPARG MDM2 CDKN2A CDK4
4
Measles 36
Show member pathways
 12.77 VIM TP53 RB1 MDM2 CDK4
5
Glioma 36
Show member pathways
 12.63 TP53 RB1 MDM2 CDKN2A CDK4
6
Mitotic G1-G1/S phases 65
Show member pathways
 12.52 TP53 RB1 MDM2 CDKN2A CDK4
7
MicroRNAs in cancer 36
12.49 VIM TP53 MDM2 HMGA2 CDKN2A
8
DNA Damage 4
12.35 VIM TP53 RB1 MDM2 CDKN2A CDK4
9
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.31 TP53 RB1 CDKN2A CDK4
10
DNA Damage Response 1
Show member pathways
 12.31 TP53 RB1 MDM2 CDKN2A CDK4
11
Cell cycle 36 1
12.28 TP53 RB1 MDM2 CDKN2A CDK4
13
Translational Control 4
12.24 YBX1 FUS EWSR1 DDIT3
14
p53 Signaling 63
Show member pathways
 12.22 TP53 RB1 MDM2 CDK4
15
Human T-cell leukemia virus 1 infection 36
12.22 TP53 RB1 GPS2 CDKN2A CDK4
16
Viral carcinogenesis 36
12.16 TP53 RB1 MDM2 CDKN2A CDK4
17
Integrated Breast Cancer Pathway 1
12.11 TP53 RB1 MDM2 CDK4
18
Cellular senescence (KEGG) 36
12.02 TP53 RB1 MDM2 CDKN2A CDK4
19
Adipogenesis 1
12.01 RB1 PPARG PPARA DDIT3
20
Spinal Cord Injury 1
11.95 VIM TP53 RB1 CDK4
21
Senescence and Autophagy in Cancer 1
11.88 TP53 RB1 MDM2 CDKN2A
22
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.83 PPARG MYOG DES CD34
23
Small cell lung cancer 36
11.82 TP53 RB1 CDK4
24
Glioblastoma Multiforme 63
11.76 TP53 RB1 MDM2 CDKN2A CDK4
25
Retinoblastoma (RB) in Cancer 1
11.74 TP53 RB1 MDM2 CDK4
26
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.71 TP53 MDM2 CDKN2A
27
Platinum drug resistance 36
11.7 TP53 MDM2 CDKN2A
28
Transcription_P53 signaling pathway 22
11.66 TP53 RB1 MDM2 CDKN2A
29
Regulation of retinoblastoma protein 1
11.57 RB1 PPARG MDM2
30
HIF1Alpha Pathway 63
11.54 TP53 MDM2 CDKN2A
31
Photodynamic therapy-induced AP-1 survival signaling. 1
11.51 TP53 RB1 CDKN2A
32
Transcriptional misregulation in cancer 36
11.45 TP53 PPARG MDM2 HMGA2 FUS EWSR1
33
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.43 TP53 MDM2 CDK4
34
Bladder cancer 36 1
11.42 TP53 RB1 MDM2 CDKN2A CDK4
35
Integrated Cancer Pathway 1
11.33 TP53 RB1 MDM2 CDK4
36
Oncogene Induced Senescence 65
11.06 TP53 MDM2 CDKN2A CDK4
37
TP53 Network 1
Show member pathways
 11.03 TP53 MDM2 CDKN2A
38
Inhibition of Ribosome Biogenesis by p14(ARF) 63
10.6 TP53 RB1 MDM2 CDKN2A
Sources

GO Terms for Liposarcoma

About this section

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.24 YBX1 VIM TSN TP53 PPARG MDM2
2 cytosol GO:0005829 10.22 YBX1 VIM TSN TP53 PPARG MDM2
3 nucleus GO:0005634 9.91 YBX1 VIM TSN TP53 RB1 PPARG
4 RNA polymerase II transcription factor complex GO:0090575 9.61 PPARG PPARA DDIT3
5 transcription factor complex GO:0005667 9.55 TP53 RB1 MYOG DDIT3 CDK4
6 protein-DNA complex GO:0032993 9.5 MYOG HMGA2 DDIT3
7 nucleoplasm GO:0005654 9.5 YBX1 TSN TP53 RB1 PPARG PPARA
8 senescence-associated heterochromatin focus GO:0035985 9.26 HMGA2 CDKN2A

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.02 TP53 RB1 PPARG MYOG CDKN2A
2 regulation of transcription, DNA-templated GO:0006355 10.02 YBX1 TP53 RB1 PPARG PPARA MYOG
3 positive regulation of apoptotic process GO:0043065 9.97 TP53 PPARG HMGA2 CDKN2A CDK4
4 positive regulation of gene expression GO:0010628 9.93 VIM TP53 MDM2 HMGA2 CDKN2A CD34
5 cell cycle GO:0007049 9.91 TP53 RB1 MYOG HMGA2 DDIT3 CDKN2A
6 positive regulation of transcription, DNA-templated GO:0045893 9.86 TP53 RB1 PPARG PPARA MYOG HMGA2
7 negative regulation of inflammatory response GO:0050728 9.84 RB1 PPARG PPARA GPS2
8 cell cycle arrest GO:0007050 9.83 TP53 RB1 DDIT3 CDKN2A
9 Ras protein signal transduction GO:0007265 9.8 TP53 RB1 CDKN2A
10 heart development GO:0007507 9.8 TP53 PPARG PPARA MDM2 MB
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 RB1 CDKN2A CDK4
12 negative regulation of cell growth GO:0030308 9.78 TP53 RB1 PPARG CDKN2A
13 negative regulation of transcription, DNA-templated GO:0045892 9.76 TP53 RB1 PPARG PPARA MDM2 HMGA2
14 replicative senescence GO:0090399 9.65 TP53 CDKN2A
15 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.65 PPARG PPARA
16 amyloid fibril formation GO:1990000 9.65 MDM2 CDKN2A
17 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.64 TP53 DDIT3
18 negative regulation of telomerase activity GO:0051974 9.64 TP53 PPARG
19 ER overload response GO:0006983 9.63 TP53 DDIT3
20 negative regulation of cholesterol storage GO:0010887 9.63 PPARG PPARA
21 cellular response to lipid GO:0071396 9.61 PPARG PPARA
22 positive regulation of cell cycle arrest GO:0071158 9.61 TP53 MYOG HMGA2
23 negative regulation of transcription by RNA polymerase II GO:0000122 9.61 YBX1 TP53 RB1 PPARG PPARA MDM2
24 cellular response to UV-C GO:0071494 9.6 TP53 MDM2
25 positive regulation of fatty acid oxidation GO:0046321 9.59 PPARG PPARA
26 negative regulation of receptor biosynthetic process GO:0010871 9.58 PPARG PPARA
27 positive regulation of fatty acid metabolic process GO:0045923 9.57 PPARG PPARA
28 enucleate erythrocyte differentiation GO:0043353 9.56 RB1 MB
29 negative regulation of sequestering of triglyceride GO:0010891 9.55 PPARG PPARA
30 cellular response to actinomycin D GO:0072717 9.51 TP53 MDM2
31 senescence-associated heterochromatin focus assembly GO:0035986 9.49 HMGA2 CDKN2A
32 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 YBX1 TP53 RB1 PPARG PPARA MYOG

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.99 YBX1 TP53 PPARG PPARA MYOG DDIT3
2 DNA-binding transcription factor activity GO:0003700 9.95 YBX1 TP53 RB1 PPARG PPARA MYOG
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 YBX1 TP53 PPARA MYOG HMGA2 DDIT3
4 identical protein binding GO:0042802 9.91 VIM TSN TP53 RB1 PPARG MDM2
5 DNA binding GO:0003677 9.9 YBX1 TSN TP53 RB1 PPARG PPARA
6 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.85 TP53 RB1 PPARG PPARA MYOG
7 transcription regulatory region DNA binding GO:0044212 9.8 TP53 PPARG HMGA2 DDIT3
8 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 YBX1 TP53 PPARA MYOG HMGA2 DDIT3
9 transcription regulatory region sequence-specific DNA binding GO:0000976 9.77 TP53 PPARG PPARA HMGA2 DDIT3
10 MDM2/MDM4 family protein binding GO:0097371 9.48 TP53 PPARA
11 disordered domain specific binding GO:0097718 9.26 TP53 RB1 MDM2 CDKN2A
12 transcription factor binding GO:0008134 9.23 TP53 RB1 PPARG PPARA HMGA2 DDIT3
Sources

Sources for Liposarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....